When we look at a term sheet, we see a single piece of an overall business strategy.
Our goal is to design a transaction, not just to monetize IP, but also to drive the growth of your entire business. We can help you in the following ways:
Start-up
License core technologies and obtain venture financing
Intervenn Bio raises a $9.4 million Series A financing led by biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV
Lundbeckfond’s sale to New Enterprise Associates 14, LP of certain royalty rights receivable in connection with the merger of Vtesse Inc. with and into a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.
FogPharma raises $66,000,000 of Series B Financing, led by 6 Dimensions Capital L.P., with participation by GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Leerink Partners and all existing Series A investors
Alnylam Pharmaceuticals, Inc.—Vir Biotechnology, Inc.
Collaboration and License Agreement
Exclusive license with Vir Biotechnology to develop and commercialize RNAi therapeutics for chronic hepatitis B virus (HBV) infection and a research collaboration for other infectious diseases
Sojournix, Inc. raises Series C equity funding from RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors
Launch of New Venture Focused on Stem Cell Transplants to Treat Early-Stage Cancers and Autoimmune Diseases, Including Exclusive License from Harvard University
Strategic Research Collaboration to Develop Treatments for Metabolic Diseases Utilizing Proprietary Antisense and RNAi Technologies (including $40 million in upfront payments, up to $871 million in milestone payments, and royalties)
Intervenn Bio raises a $9.4 million Series A financing led by biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV
Lundbeckfond’s sale to New Enterprise Associates 14, LP of certain royalty rights receivable in connection with the merger of Vtesse Inc. with and into a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.
FogPharma raises $66,000,000 of Series B Financing, led by 6 Dimensions Capital L.P., with participation by GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Leerink Partners and all existing Series A investors
Alnylam Pharmaceuticals, Inc.—Vir Biotechnology, Inc.
Collaboration and License Agreement
Exclusive license with Vir Biotechnology to develop and commercialize RNAi therapeutics for chronic hepatitis B virus (HBV) infection and a research collaboration for other infectious diseases
Sojournix, Inc. raises Series C equity funding from RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors
